![Biocon wins US patent battle against Sanofi on insulin biosimilar](https://images.assettype.com/fortuneindia%2F2021-12%2Fa0cc9b60-1be7-4f0c-ae27-eaa5d08ce2c6%2Fbiocon_pic.jpg?w=300&q=95)
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.